AI
Tuesday, March 17, 2026 12:56:33 PM
Thanks for sharing your free x-pertise 😶
And thanks for highlighting the topic of ovarian cancer…
The forthcoming COMBO trial for ovarian cancer involves the polarized aDC1 platform …
The NIH database entry for Dr. Kalinski’s previous grant award may provide insight into the potential design of the ovarian cancer combo trial:
🇺🇸U.S. National Institutes of Health Grants Database
Perhaps even more valuable than the funding itself, the validation that comes with a rigorously peer-reviewed grant award is immensely significant!
Dr. Kalinski
University of Pittsburgh Hillman Cancer Center
The polarized aDC1 platform has also been studied in breast cancer with promising results…
The Dava Oncology Breast Cancer Summit was a noteworthy event last August—deserved more attention. NWBO’s polarized aDC1 platform technology was featured, & combo with checkpoint blockade was highlighted!
Dr. Shipra Gandhi was the principal on the aDC1 combo trial NCT04348747 before joining the Winship Cancer Institute at Emory University. Dr. Sheheryar Kabraji is the current principal of the study, & he also attended the conference.
Starting Now: Cellular Therapies and Vaccine Strategies
— DAVA Oncology (@DAVAOnc) August 23, 2025
Moderated by: Dr. Vinay Jain #DAVABreast pic.twitter.com/fl2E6KiHtB
Starting Now: Novel Immune Checkpoint Approaches
— DAVA Oncology (@DAVAOnc) August 23, 2025
Moderated by: @Dr_RShatsky @UCSDHealth #DAVABreast pic.twitter.com/MAopMWbirC
Can we re-engage anti-HER2/3 immunity in brain-metastatic breast cancer? Dr. @gandhi_shipra from @WinshipAtEmory presents a dendritic cell vaccine + PD-1 combo approach in CNS disease (NCT04348747), with a novel Th1/CTL-driven strategy at #DAVABreast #BreastCancer pic.twitter.com/OTgEhph8CR
— DAVA Oncology (@DAVAOnc) August 21, 2025
Thanks @DAVAOnc for a great week full of new learning and connections and renewing old friendships https://t.co/4hxE4obErG
— Sheheryar Kabraji (@SKabrajiMD) August 25, 2025
ASCO 2025 Abstract
AI Fact-Checking
I am a long NWBO shareholder. Views expressed are my own, and I have no affiliation with the company.
